Effect of mifepristone on the expression of endometrial secretory leukocyte protease inhibitor in new medroxyprogesterone acetate users.
The effect of mifepristone on the expression of secretory leukocyte protease inhibitor (SLPI) in the endometrium of women using depot medroxyprogesterone acetate (DMPA) was investigated in this randomized, placebo-controlled trial. The study showed that the administration of DMPA led to a substantial inhibition of endometrial SLPI protein and mRNA, and that the addition of mifepristone to DMPA-exposed endometrium partially restored the expression of glandular SLPI.
D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage; D003280:Contraceptives, Oral, Synthetic / Q000008:administration & dosage; D004347:Drug Interactions; D004717:Endometrium / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D015870:Gene Expression / Q000528:radiation effects; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D015735:Mifepristone / Q000378:metabolism*; D015990:Placebo Effect; D053481:Secretory Leukocyte Peptidase Inhibitor / Q000378:metabolism*
D003271:Contraceptive Agents, Female; D003280:Contraceptives, Oral, Synthetic; D053481:Secretory Leukocyte Peptidase Inhibitor; D015735:Mifepristone; D017258:Medroxyprogesterone Acetate